Wellington Management Group LLP Purchases New Stake in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Wellington Management Group LLP bought a new position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,314 shares of the medical instruments supplier's stock, valued at approximately $1,888,000. Wellington Management Group LLP owned approximately 0.26% of Mesa Laboratories as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the stock. FMR LLC increased its position in shares of Mesa Laboratories by 34.1% during the third quarter. FMR LLC now owns 393 shares of the medical instruments supplier's stock worth $51,000 after acquiring an additional 100 shares in the last quarter. Amundi lifted its holdings in shares of Mesa Laboratories by 81.6% in the fourth quarter. Amundi now owns 661 shares of the medical instruments supplier's stock valued at $91,000 after purchasing an additional 297 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Mesa Laboratories during the fourth quarter worth about $132,000. Captrust Financial Advisors bought a new position in shares of Mesa Laboratories during the third quarter worth about $207,000. Finally, Berry Wealth Group LP raised its position in Mesa Laboratories by 5.3% in the 4th quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier's stock valued at $219,000 after buying an additional 83 shares during the last quarter. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Mesa Laboratories

In other news, CEO Gary M. Owens sold 21,000 shares of the business's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the transaction, the chief executive officer now directly owns 43,337 shares in the company, valued at $5,369,887.67. The trade was a 32.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.40% of the company's stock.

Mesa Laboratories Stock Down 0.8 %

NASDAQ:MLAB traded down $0.91 during trading hours on Friday, reaching $112.01. 40,279 shares of the stock were exchanged, compared to its average volume of 39,087. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.71 and a quick ratio of 0.53. Mesa Laboratories, Inc. has a twelve month low of $83.68 and a twelve month high of $155.12. The stock has a market cap of $608.66 million, a PE ratio of -2.42 and a beta of 0.92. The firm has a 50 day moving average of $127.65 and a 200 day moving average of $127.80.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last released its earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, beating analysts' consensus estimates of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 104.92% and a positive return on equity of 30.23%. On average, equities analysts expect that Mesa Laboratories, Inc. will post 8 earnings per share for the current year.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 16th. Investors of record on Friday, May 30th will be given a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, May 30th. This represents a $0.64 annualized dividend and a yield of 0.57%. Mesa Laboratories's dividend payout ratio (DPR) is presently -1.38%.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.